Literature DB >> 24929618

Mesoporous NaYbF4@NaGdF4 core-shell up-conversion nanoparticles for targeted drug delivery and multimodal imaging.

Liangjun Zhou1, Xiaopeng Zheng1, Zhanjun Gu2, Wenyan Yin3, Xiao Zhang3, Longfei Ruan3, Yanbo Yang3, Zhongbo Hu4, Yuliang Zhao5.   

Abstract

We developed a facile strategy to obtain a new kind of mesoporous core-shell structured up-conversion nanoparticles (mUCNPs), composed of a NaYbF4:2%Er core and a mesoporous NaGdF4 shell. This mesoporous shell not only enhanced the up-conversion luminescence but also endowed many other functionalities of the nanoparticles such as drug delivery and bio-imaging capabilities. Moreover, after being conjugated with polyethylenimine (PEI) and folic acid (FA), core-shell mUCNPs exhibited good water dispersibility, enhanced drug delivery efficiency, and remarkable targeting ability to cancer cells. To certify the folate receptors (FR)-mediated targeted drug delivery, cell viability assay, cell up-conversion luminescence imaging and flow cytometry analysis were carried out. Furthermore, apart from the application for targeted drug delivery, the as-prepared core-shell mUCNPs could also be employed as the contrast agents for X-ray computed tomography (CT) and magnetic resonance (MR) imaging, because of the strong X-ray attenuation ability of Yb and high longitudinal molar relaxivity (r1) of Gd in the nanoparticles, providing the potential for simultaneously bio-imaging and cancer-targeting therapy.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Core-shell; Mesoporous; Multimodality biomedical imaging; Targeted drug delivery; Up-conversion nanoparticles

Mesh:

Substances:

Year:  2014        PMID: 24929618     DOI: 10.1016/j.biomaterials.2014.05.051

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

Review 1.  Theragnostic potentials of core/shell mesoporous silica nanostructures.

Authors:  Aswathy Ravindran Girija; Sivakumar Balasubramanian
Journal:  Nanotheranostics       Date:  2019-01-01

Review 2.  Recent Advances in Higher-Order, Multimodal, Biomedical Imaging Agents.

Authors:  James Rieffel; Upendra Chitgupi; Jonathan F Lovell
Journal:  Small       Date:  2015-07-16       Impact factor: 13.281

3.  Enhanced cell uptake of fluorescent drug-loaded nanoparticles via an implantable photothermal fibrous patch for more effective cancer cell killing.

Authors:  Yangyang Li; Yike Fu; Zhaohui Ren; Xiang Li; Chuanbin Mao; Gaorong Han
Journal:  J Mater Chem B       Date:  2017-09-07       Impact factor: 6.331

4.  Recent advances in porous nanostructures for cancer theranostics.

Authors:  Jinping Wang; Beilu Zhang; Jingyu Sun; Wei Hu; Hongjun Wang
Journal:  Nano Today       Date:  2021-04-08       Impact factor: 18.962

5.  Enhancing anti-tumor efficacy of Doxorubicin by non-covalent conjugation to gold nanoparticles - in vitro studies on feline fibrosarcoma cell lines.

Authors:  Michał Wójcik; Wiktor Lewandowski; Magdalena Król; Karol Pawłowski; Józef Mieczkowski; Roman Lechowski; Katarzyna Zabielska
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

6.  Construction of pH-responsive and up-conversion luminescent NaYF₄:Yb³⁺/Er³⁺@SiO₂@PMAA nanocomposite for colon targeted drug delivery.

Authors:  Boshi Tian; Shaohua Liu; Wei Lu; Lin Jin; Qingfeng Li; Yurong Shi; Chunyang Li; Zhenling Wang; Yaping Du
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

7.  Antimicrobial performance of mesoporous titania thin films: role of pore size, hydrophobicity, and antibiotic release.

Authors:  Saba Atefyekta; Batur Ercan; Johan Karlsson; Erik Taylor; Stanley Chung; Thomas J Webster; Martin Andersson
Journal:  Int J Nanomedicine       Date:  2016-03-10

8.  Toxicity Mechanism of Low Doses of NaGdF₄:Yb3+,Er3+ Upconverting Nanoparticles in Activated Macrophage Cell Lines.

Authors:  Edyta Wysokińska; Jakub Cichos; Agnieszka Kowalczyk; Mirosław Karbowiak; Leon Strządała; Artur Bednarkiewicz; Wojciech Kałas
Journal:  Biomolecules       Date:  2019-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.